Open AccessGerminal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case
Author(s) -
Fang Liu,
Fei Qi,
Xiuying Zhang,
Mei Cao,
Shiguang Peng
Publication year - 2022
Publication title -
clinical, cosmetic and investigational dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 35
ISSN - 1178-7015
DOI - 10.2147/ccid.s373937
Subject(s) - vincristine , prednisone , medicine , rituximab , cyclophosphamide , lymphoma , chop , diffuse large b cell lymphoma , chemotherapy , doxorubicin , complete remission , oncology , dermatology
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and the most aggressive type of the cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. It mostly affects elderly women, with a 5-year survival rate of 50% if not efficiently treated. We present a 28-year-old male patient with indolent PCDLBCL-LT who reached nearly 100% clearance after six rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy sessions.